Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Investegate announcements from Sanofi - Aventis Groupe, Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
Dupixent (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine specifically indicated
If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in.
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.